Concerns following event on HAVEN1 trial.
Tafinlar and Mekinist looks set for approval in BRAF V600 lung cancer
10/03/2017February 8, 2017
02/11/2016November 1, 2016
22/11/2016October 20, 2016
‘Pricing and Market Access Outlook: 2017 Edition’ includes fresh analysis from QuintilesIMS of market forces and pricing policy based on facts and figures behind approvals of new molecular entities in 2015.